Canaccord Genuity reduced its rating on USANA Health Sciences USNA from Buy to Hold and lowered its price target from $60 to $40.
Canaccord Genuity commented, "While the beginnings of improvement in US sales trends and a modest valuation had attracted us to USNA shares, we expect that another management transition is likely to inhibit a normalization of the valuation. … While USNA's valuation is modest, and even discounted relative to its peers, we expect added organizational risk will lead to a perpetuated valuation discount and the shares could lag its peers in any normalization of the sector valuations."
USANA Health Sciences closed at $38.42 on Thursday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in